EA201991164A1 - APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR - Google Patents

APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR

Info

Publication number
EA201991164A1
EA201991164A1 EA201991164A EA201991164A EA201991164A1 EA 201991164 A1 EA201991164 A1 EA 201991164A1 EA 201991164 A EA201991164 A EA 201991164A EA 201991164 A EA201991164 A EA 201991164A EA 201991164 A1 EA201991164 A1 EA 201991164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
pertuzumab
cancer
treatment
application
Prior art date
Application number
EA201991164A
Other languages
Russian (ru)
Inventor
Сридхара Алаваттам
Лукас К. Амлер
Кристина Х. Де Толедо Пелизон
Марк К. Беньюнс
Эмма Л. Кларк
Зефаниа В. Квонг Гловер
Лада Митчелл
Джаянтха Ратнаяк
Грэхам А. Росс
Ру-Амир Уокер
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of EA201991164A1 publication Critical patent/EA201991164A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящая заявка описывает применение и промышленные изделия, включающие пертузумаб, наилучший в своем классе ингибитор димеризации HER2. В частности, заявка относится к способам для продления выживаемости без прогрессирования в популяции пациентов с HER2-положительным раком молочной железы; к сочетанию двух антител против HER2 для лечения HER2-положительного рака без повышения кардиотоксичности; к лечению ранней стадии HER2-положительного рака молочной железы; к лечению HER2-положительного рака путем совместного введения смеси пертузумаба и трастузумаба из одного пакета для внутривенного введения; к лечению HER2-положительного метастатического рака желудка; к лечению HER2-положительного рака молочной железы пертузумабом, трастузумабом и винорелбином; к лечению HER2-положительного рака молочной железы пертузумабом, трастузумабом и ингибитором ароматазы и к лечению рака яичника с низким уровнем HER3, первичной перитонеальной злокачественной опухоли или злокачественной опухоли фаллопиевых труб. Заявка также описывает промышленное изделие, включающее в себя флакон с пертузумабом внутри и вкладыш в упаковку, предоставляющий данные по безопасности и/или данные по эффективности; способ производства промышленного изделия и способ для обеспечения безопасного и эффективного применения пертузумаба, относящийся к изделию. Кроме того, заявка описывает пакет для внутривенного (в/в) введения, содержащий стабильную смесь пертузумаба и трастузумаба, подходящую для введения пациенту с раком.This application describes application and industrial products including pertuzumab, the best-in-class HER2 dimerization inhibitor. In particular, the application relates to methods for prolonging progression-free survival in a population of patients with HER2-positive breast cancer; a combination of two antibodies against HER2 for the treatment of HER2-positive cancer without increasing cardiotoxicity; treatment of an early stage of HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of pertuzumab and trastuzumab from a single intravenous packet; treatment of HER2-positive metastatic cancer of the stomach; treatment of HER2-positive breast cancer with pertuzumab, trastuzumab and vinorelbine; treatment of HER2-positive breast cancer with pertuzumab, trastuzumab and an aromatase inhibitor; and treatment of ovarian cancer with low HER3, a primary peritoneal cancer or a fallopian tube cancer. The application also describes an industrial product including a bottle with pertuzumab inside and a package insert providing safety data and / or efficacy data; a method of manufacturing an industrial product; and a method for providing safe and effective use of pertuzumab related to the product. In addition, the application describes a package for intravenous (iv) administration containing a stable mixture of pertuzumab and trastuzumab, suitable for administration to a patient with cancer.

EA201991164A 2012-08-29 2012-10-11 APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR EA201991164A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261694584P 2012-08-29 2012-08-29

Publications (1)

Publication Number Publication Date
EA201991164A1 true EA201991164A1 (en) 2019-09-30

Family

ID=68000202

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991164A EA201991164A1 (en) 2012-08-29 2012-10-11 APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR

Country Status (1)

Country Link
EA (1) EA201991164A1 (en)

Similar Documents

Publication Publication Date Title
PH12019500519A1 (en) Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
NZ719784A (en) Specific anti-cd38 antibodies for treating human cancers
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EA201591371A1 (en) Pyridine derivatives as easily degraded inhibitors ROCK
EA201591166A1 (en) AUTOTAXIN INHIBITORS
MX2015014751A (en) Compositions and methods for the treatment of immunodeficiency.
MX2015015110A (en) Antibody specifically binding to her2.
MX2019013753A (en) Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations.
MX2018006953A (en) Monomaleimide-functionalized platinum compounds for cancer therapy.
AU2018256669A1 (en) Combination therapy
HRP20230523T1 (en) Antitumor agent and antitumor effect enhancer
MX2017014396A (en) Treatment for multiple myeloma (mm).
MX2017013358A (en) Methods for treating cancer.
BR102012028120B8 (en) USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG
MX2016006894A (en) Combination therapy comprising an inhibitor of jak, cdk and pim.
EA201400495A1 (en) SELECTIVE INHIBITORS THROUGH THE INTERACTION OF THE RECEPTOR OF FIBROBLAST GROWTH FACTOR AND FRS2, FOR PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
EA201991164A1 (en) APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR
MX2016006927A (en) Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis.
MX2015016893A (en) Combination of ro5503781 and capecitabine for cancer therapy.
EA201791075A1 (en) METHODS OF TUMOR TREATMENT USING CDIS × CD20 BISPECIFIC ANTIBODIES
UA105159C2 (en) Method for treating recurrent varicose of lower limbs